Pharmaceutical Business review

VisiVite introduces new macular health formula

Based on the National Eye Institute’s Age-Related Eye Disease Studies (AREDS and AREDS2), AREDS2 Silver supplies antioxidants for macular health without the high levels of zinc that may cause issues in those with zinc sensitivities and allergies.

The first AREDS study found that an antioxidant supplement of beta carotene, vitamin C, vitamin E and zinc appeared to reduce the risk of age-related macular changes.

AREDS2, its follow-up study, revealed that plant-based antioxidants lutein and zeaxanthin could be substituted for beta-carotene, which is associated with health risks in smokers and absorption challenges in others.

AREDS2 also found that there were no significant differences between low dose zinc and high dose zinc in the formula’s success.

VisiVite’s AREDS2 Silver is calibrated to match these findings, supplying a gentle 40 mg zinc serving that may be preferable for those who have zinc sensitivities.

AREDS2 Silver also features:

– FloraGLO® Lutein (10 mg): A macular antioxidant sourced from marigold flowers

– OmniXan Zeaxanthin (2mg): Prized paprika-sourced broad-spectrum antioxidants

– Vitamin C (500 mg) and Vitamin E (400 IU): Bioavailable and natural antioxidants

Vitamin Science and VisiVite product formulator Dr Paul Krawitz noted that it is the company’s mission at VisiVite to provide eye health supplements that are constantly evolving and updating to match the latest scientific research.

"With our new AREDS2 Silver formula, we are leveraging the newest findings that suggest lower dose zinc works just as well as higher doses. AREDS2 Silver enables zinc-sensitive populations to nourish their eyes with an evidence-backed antioxidant complex that is both well-tolerated and highly effective in promoting macular health," Dr Krawitz added.